1)Hogg RS, et al:Rate of disease progression by baseline CD4 cell count and viral load after initiating triple drug therapy. JAMA 286:2597-2599, 2001
2)Strategies for Management of Antiretroviral Therapy(SMART)study Group:Major clinical outcome in antiretroviral therapy(ART)-naïve participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 197:1084-1086, 2008
3)Havlir DV, Barnes PF:Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340:367-373, 1999
4)Little RF, et al:HIV-associated non-hodgkin lymphoma:incidence, presentation, and prognosis. JAMA 285:1880-1885, 2001
5)Bettaieb A, et al:Cross-reactive antibodies between HIV-gp120 and platelet gpIIIa(CD61) in HIV-related immune thrombocytopenic purpura. Clin Exp Immunol 103:19-23, 1996
6)Moses AV, et al:Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 87:919-925, 1996
7)Coldiron BM, Bergstresser PR:Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 125:357-361, 1988
8)Kerr AR, Ship JA:Management strategies for HIV-associated aphthous stomatitis. Am J Clin Dermatol 4:669-680, 2003
9)Uronis HE, Bendell JC:Anal cancer:an overview. Oncologist 12:524-534, 2007
10)Schacker T, et al:Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125:257-264, 1996
11)Cohen MS:HIV and sexual transmitted diseases:lethal synergy. Top HIV Med 12:104-107, 2004
12)Branson BM, et al:Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 55(RR14):1-17, 2006